MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Innoviva Inc

Fechado

SetorSaúde

19.16 0.84

Visão Geral

Variação de preço das ações

24h

Atual

Mín

18.86

Máximo

19.24

Indicadores-chave

By Trading Economics

Rendimento

-67M

-47M

Vendas

-3.2M

89M

P/E

Médio do Setor

51.694

39.564

Margem de lucro

-52.559

Funcionários

127

EBITDA

-63M

-27M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+99.53% upside

Dividendos

By Dow Jones

Próximos Ganhos

29 de jul. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

30M

1.2B

Abertura anterior

18.32

Fecho anterior

19.16

Sentimento de Notícias

By Acuity

14%

86%

17 / 376 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

Innoviva Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

9 de jul. de 2025, 15:46 UTC

Grandes Movimentos do Mercado

BitMine Shares Fall After Closing of $250 Million Private Placement

9 de jul. de 2025, 23:44 UTC

Conversa de Mercado

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9 de jul. de 2025, 23:42 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

9 de jul. de 2025, 23:42 UTC

Conversa de Mercado

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9 de jul. de 2025, 22:59 UTC

Conversa de Mercado

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9 de jul. de 2025, 22:59 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

9 de jul. de 2025, 20:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Health Care Roundup: Market Talk

9 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

9 de jul. de 2025, 20:26 UTC

Ganhos

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9 de jul. de 2025, 19:18 UTC

Conversa de Mercado

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9 de jul. de 2025, 19:03 UTC

Conversa de Mercado

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9 de jul. de 2025, 18:31 UTC

Conversa de Mercado

Some Fed Officials Supported Considering July Cut -- Market Talk

9 de jul. de 2025, 17:07 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk -2-

9 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

9 de jul. de 2025, 16:20 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Health Care Roundup: Market Talk

9 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

9 de jul. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

9 de jul. de 2025, 16:14 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

9 de jul. de 2025, 16:14 UTC

Conversa de Mercado

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9 de jul. de 2025, 16:14 UTC

Aquisições, Fusões, Aquisições de Empresas

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9 de jul. de 2025, 16:12 UTC

Conversa de Mercado

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9 de jul. de 2025, 16:08 UTC

Conversa de Mercado

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9 de jul. de 2025, 15:31 UTC

Grandes Movimentos do Mercado

BitMine Shares Fall After Closing of $250M Private Placement

9 de jul. de 2025, 15:31 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9 de jul. de 2025, 15:27 UTC

Conversa de Mercado

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9 de jul. de 2025, 14:36 UTC

Aquisições, Fusões, Aquisições de Empresas

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9 de jul. de 2025, 14:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9 de jul. de 2025, 14:26 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

9 de jul. de 2025, 14:26 UTC

Conversa de Mercado

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Comparação entre Pares

Variação de preço

Innoviva Inc Previsão

Preço-alvo

By TipRanks

99.53% parte superior

Previsão para 12 meses

Média 38.25 USD  99.53%

Máximo 55 USD

Mínimo 21.5 USD

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Innoviva Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

1

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

18.57 / 18.75Suporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Neutral Evidence

Sentimento

By Acuity

17 / 376 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.